AstraZeneca Reports Phase 3 Data for Danicopan in Psoriatic arthritis

AstraZeneca today announced Phase 3 results for danicopan in patients with psoriatic arthritis. The study demonstrated that danicopan significantly improves overall survival compared to standard of care or placebo. These results provide important insights into the treatment of psoriatic arthritis and support the continued development of danicopan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.